Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998
Autore:
Dawkins, K; Lieberman, JA; Lebowitz, BD; Hsiao, JK;
Indirizzi:
Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA Univ N CarolinaChapel Hill NC USA 27599 chiat, Chapel Hill, NC 27599 USA NIMH,7Adult Geriatr Treatment & Prevent Intervent Res B, Rockville, MD 2085 NIMH Rockville MD USA 20857 & Prevent Intervent Res B, Rockville, MD 2085 NIMH, Schizophrenia Bulletin, Rockville, MD 20857 USA NIMH Rockville MD USA 20857 hizophrenia Bulletin, Rockville, MD 20857 USA
Titolo Testata:
SCHIZOPHRENIA BULLETIN
fascicolo: 2, volume: 25, anno: 1999,
pagine: 395 - 404
SICI:
0586-7614(1999)25:2<395:APAF-N>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
TREATMENT-REFRACTORY SCHIZOPHRENIA; TREATMENT-RESISTANT SCHIZOPHRENIA; CHILDHOOD-ONSET SCHIZOPHRENIA; BLIND OLANZAPINE TRIAL; CLOZAPINE TREATMENT; TARDIVE-DYSKINESIA; RISK-FACTORS; HALOPERIDOL; RISPERIDONE; PLACEBO;
Keywords:
antipsychotic drugs; atypical antipsychotic drugs; typical antipsychotic drugs; clozapine; risperidone; olanzapine; quetiapine; ziprasidone;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Dawkins, K Univ N Carolina, Dept Psychiat, Campus Box 7160, Chapel Hill, NC 27599 USA Univ N Carolina Campus Box 7160 Chapel Hill NC USA 27599 99 USA
Citazione:
K. Dawkins et al., "Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998", SCHIZO BULL, 25(2), 1999, pp. 395-404

Abstract

A workshop on "Antipsychotics: Past and Future" was convened by the National Institute of Mental Health (NIMH), Division of Services and InterventionResearch (DSIR), on July 14, 1998, to review the results of recent antipsychotic drug research, discuss current standards of treatment, and identify areas needing further study. There has been a proliferation of new antipsychotic medications and a rapid increase in their clinical utilization. The new atypicals are beginning to supplant the older typical neuroleptic antipsychotics, and the scientific and ethical issues raised by this transition prompted the workshop. Given the apparent, albeit not fully defined, advantages of atypical drugs, particularly their safety profiles, the question is whether more comparisons with typical antipsychotics are warranted and whether clinical trial designs warrant (or would be justified in) the inclusionof typical drugs as standard active comparators. Workshop participants-including clinical researchers, patient advocates, bioethicists, and NIMH staff-discussed the conclusions drawn from current data, ethical issues for subjects in clinical trials, funding for ongoing studies using typical agents,and appropriate comparators for trials using atypical agents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 21:35:55